Physician profile
Nalo Ford
NPI 1780265181
$7,745.50
in general payments reported to CMS, 2019-2025
30 companies · $1,787 in 2025
The $1,787 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $283 · 2022: $1,949 · 2023: $1,915 · 2024: $1,812 · 2025: $1,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,514.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,332.16 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $612.36 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $610.71 | 2022-2025 | Ajovy, Austedo |
| E.R. Squibb & Sons, L.L.C. | $605.43 | 2024-2025 | Cobenfy |
| Novo Nordisk INC | $485.74 | 2021-2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $340.53 | 2023 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $280.15 | 2022-2025 | Ingrezza |
| Emd Serono, INC. | $254.51 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $229.96 | 2022-2024 | |
| Coloplast Corp | $216.85 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $211.14 | 2023 | Quviviq |
| Aimmune Therapeutics, INC. | $205.04 | 2024 | |
| Alkermes, INC. | $199.86 | 2023-2025 | Lybalvi, Aristada |
| Sage Therapeutics, LLC | $197.77 | 2025 | |
| Biogen, INC. | $192.58 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $182.47 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $160.84 | 2024 | Qelbree |
| Amgen INC. | $140.93 | 2024 | |
| Boston Scientific Corporation | $138.43 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $134.52 | 2022 | |
| Indivior INC. | $129.63 | 2023-2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2022 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Krystexxa |
| Vanda Pharmaceuticals INC. | $110.76 | 2025 | Hetlioz, Fanapt |
| Sanofi Pasteur INC. | $107.25 | 2022 | |
| Vertos Medical, INC. | $107.22 | 2023 | Mild Device Kit |
| Bayer Healthcare Pharmaceuticals INC. | $107.10 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $96.66 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $72.19 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Tms Neurohealth Centers INC. | $32.72 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nalo Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.